Researchers at the University of Nebraska and the Texas Biomedical Research Institute have recently published a
peer-reviewed article suggesting that
CBD could be included in the treatment regimen for the COVID-19 coronavirus. Researchers say that both THC and CBD appear to reduce the severe lung inflammation associated with the virus.
The article was published in this month's issue of
Brain, Behavior, and Immunity, the authors concluded that, "Collectively, these findings support the investigation of cannabinoids as a plausible option to be added as an adjunct to Remdesivir or any new antivirals on SARS-CoV2 induced lung inflammation."
The authors of the paper pointed to numerous studies that showed the anti-inflammatory properties of CBD. THC is known to have anti-inflammatory properties as well, but because some patients would prefer to not have the psychoactive side effects, the researchers chose to focus specifically on CBD.
"Unlike THC, CBD has a
high margin of safety and is well tolerated pharmacologically even after treatments of up to 1500 mg/day for two weeks in both animals and humans, which suggests its feasibility to reduce SARS-CoV2 induced lung inflammation/pathology and disease severity," the article said.
Comment: See also: